Product Description
P2B001 is a novel, once-daily combination of extended-release (ER) pramipexole, a low dose dopamine agonist (0.6mg), and rasagiline, a low dose MAO-B inhibitor (0.75mg), developed specifically for the treatment of Parkinson’s Disease (PD). The low doses utilized in P2B001 are not currently available on the market and the ER formulation of rasagiline is a proprietary dosage form of Pharma Two B. The combination showed a significant increase in striatal dopaminergic transmission via distinct and potentially synergistic mechanisms in a mouse model and the extended-release profile resulted in a further increase in dopamine levels. (Sourced from: https://pharma2b.com/p2b001/about)
Mechanisms of Action: D2 Agonist|D3 Agonist|MAO-b Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pharma Two B
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2017-001420-21 | P3 |
Completed |
Parkinson's Disease |
2021-08-24 |
|
| P2B001/003 | P3 |
Completed |
Parkinson's Disease |
2021-08-23 |
|
| P2B001/001 | P3 |
Completed |
Parkinson's Disease |
2015-05-01 |